Last updated: September 3, 2026
Imipenem-cilastatin is a mature, off-patent carbapenem antibiotic used primarily in hospitals for serious bacterial infections. Imipenem provides antibacterial activity, while cilastatin inhibits renal dehydropeptidase-I and prevents imipenem degradation. The original branded product, Primaxin, lost meaningful exclusivity years ago. Current value is concentrated in generic injectable supply, hospital tenders, manufacturing reliability, and differentiated combination products such as imipenem-cilastatin-relebactam.
The market has shifted from branded pricing to volume-driven procurement. Revenue from the original imipenem-cilastatin product has declined sharply since generic entry, while demand remains supported by antimicrobial resistance, intensive-care use, and limited substitutes for certain multidrug-resistant infections.
What is imipenem-cilastatin and how is it used?
Imipenem-cilastatin is an intravenous antibacterial combination. Imipenem is a broad-spectrum carbapenem that binds penicillin-binding proteins and inhibits bacterial cell-wall synthesis. Cilastatin is not an antibacterial agent. It inhibits renal metabolism of imipenem, increasing urinary and systemic exposure.
The U.S. label identifies the combination for serious infections caused by susceptible organisms, including:
- Lower respiratory tract infections
- Intra-abdominal infections
- Complicated urinary tract infections
- Gynecologic infections
- Septicemia
- Bone and joint infections
- Skin and skin-structure infections
- Endocarditis in selected circumstances
The product is administered intravenously and is generally used in inpatient settings. Its clinical value is highest when broad empiric coverage is needed or when resistance limits the utility of narrower beta-lactams.
Imipenem-cilastatin does not reliably treat infections caused by organisms with metallo-beta-lactamases, and resistance mechanisms such as carbapenemases can substantially reduce activity. Stewardship programs therefore restrict use in many hospitals.
When did imipenem-cilastatin lose exclusivity?
The original Merck product was commercialized under the Primaxin brand in the 1980s. Core composition and product patents expired long before the current market period. FDA regulatory exclusivity also expired decades ago.
| Milestone |
Approximate timing |
Commercial effect |
| Original Primaxin approval |
1985 |
Established imipenem-cilastatin as a hospital carbapenem |
| Core product protection |
Expired before the modern generic era |
Removed the primary barrier to ANDA entry |
| Generic injectable competition |
Established by the 2000s |
Shifted purchasing to price and supply |
| Recarbrio approval |
2019 |
Created a newer, protected imipenem-based combination |
| Current market |
Mature generic market |
Revenue depends on volume, tenders, and supply continuity |
The exact original patent portfolio included composition, formulation, and manufacturing claims associated with imipenem and cilastatin. Those claims no longer provide a commercially meaningful barrier to standard imipenem-cilastatin products in the United States.
What is the FDA regulatory status of imipenem-cilastatin?
Imipenem-cilastatin is an FDA-approved prescription antibacterial product administered by intravenous infusion. The original branded product is associated with NDA 050587. Generic versions are approved through abbreviated new drug applications.
The product has no meaningful remaining new-drug exclusivity. Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements applicable to injectable products. Manufacturing controls, sterility assurance, stability, container closure, and active pharmaceutical ingredient quality are central approval and commercial requirements.
The main regulatory distinction is between:
- Standard imipenem-cilastatin injection.
- Imipenem-cilastatin-relebactam, marketed as Recarbrio.
- Other carbapenems, including meropenem and ertapenem.
Recarbrio is not a generic extension of standard imipenem-cilastatin. It adds relebactam, a beta-lactamase inhibitor, and is positioned for infections involving selected resistant pathogens.
What is the Orange Book status of imipenem-cilastatin?
Standard imipenem-cilastatin has no commercially important remaining Orange Book patent barrier associated with the original Primaxin product. The core product is therefore exposed to generic competition.
Orange Book analysis must distinguish the legacy combination from Recarbrio. Recarbrio has separate patents and regulatory exclusivity associated with relebactam, the combination product, and approved methods of use. Those protections do not restore exclusivity to ordinary imipenem-cilastatin.
| Product |
Active ingredients |
Market status |
Patent position |
| Primaxin and authorized or branded legacy products |
Imipenem-cilastatin |
Mature product |
Core exclusivity expired |
| Generic imipenem-cilastatin |
Imipenem-cilastatin |
Competitive injectable market |
Generally exposed to ANDA competition |
| Recarbrio |
Imipenem-cilastatin-relebactam |
Protected branded combination |
Separate patent and exclusivity analysis required |
FDA Orange Book entries and patent certifications can change as products are listed, delisted, or updated. The commercial conclusion remains stable: ordinary imipenem-cilastatin is a generic market, while Recarbrio is a separate protected product.
How many patents cover imipenem-cilastatin?
The original imipenem-cilastatin estate included multiple patent families, but the key commercial claims have expired. Current patent risk for standard products is low relative to newer antibacterial combinations.
Historically relevant claim categories included:
- Imipenem composition claims
- Cilastatin combination claims
- Pharmaceutical formulation claims
- Injectable preparation claims
- Manufacturing and purification processes
- Treatment methods using the combination
Patent expiry removed the central barrier to generic entry. Residual patents, if any, are more likely to concern specific manufacturing processes, formulations, presentations, or newer combinations than the basic use of imipenem-cilastatin.
A company evaluating entry should separate freedom to operate for the active ingredients from freedom to operate for:
- A specific crystalline or solid-state form
- A particular vial or premix presentation
- A room-temperature or frozen formulation
- A manufacturing route
- A combination with relebactam
- A branded method of use
Are there Paragraph IV challenges for imipenem-cilastatin?
Paragraph IV litigation is not a material current market driver for ordinary imipenem-cilastatin. The product has been generic for many years, and the primary product patents expired long ago.
Generic applicants may still use Paragraph IV certifications when challenging listed patents associated with a specific product or presentation. That issue is more relevant to newer imipenem-based products, especially Recarbrio, than to legacy imipenem-cilastatin.
For standard imipenem-cilastatin, the relevant entry pathways are generally:
- ANDA approval against an established reference product
- Abbreviated applications for injectable presentations
- Product-specific manufacturing approvals
- Procurement qualification with hospital systems and government purchasers
The absence of major current Paragraph IV activity does not eliminate commercial barriers. It shifts the competitive focus to FDA inspection outcomes, manufacturing capacity, product quality, and contracting.
What formulations are protected by imipenem-cilastatin patents?
The commercially important formulation is a sterile intravenous powder that is reconstituted before administration. Generic manufacturers compete through equivalent vial strengths, labeling, stability, storage, and compatibility characteristics.
Formulation and presentation issues can affect market access even when the active ingredient is off patent. Relevant technical factors include:
- Sterile lyophilized or dry powder manufacture
- Imipenem chemical stability
- Cilastatin compatibility
- Reconstitution time
- Infusion compatibility
- Vial size and dose flexibility
- Storage temperature
- Beyond-use dating
- Hospital pharmacy workflow
Hospitals may favor products with longer dating, simpler preparation, or reliable supply even when prices are similar. These factors can create practical differentiation without creating durable patent exclusivity.
How strong is the patent estate for imipenem-cilastatin?
The legacy patent estate is weak as a market exclusion tool because the basic product claims have expired. Technical know-how remains more important than patent protection.
| Risk category |
Assessment |
| Core active-ingredient patent risk |
Low |
| Composition-of-matter exclusivity |
Expired |
| Standard formulation risk |
Low to moderate, depending on presentation |
| Manufacturing-process risk |
Product-specific |
| Method-of-use risk |
Low for established labeled indications |
| Recarbrio combination risk |
Material and separate from legacy product |
| Biosimilar risk |
Not applicable |
The most relevant barriers are operational. Imipenem is chemically sensitive and requires controlled manufacturing. Cilastatin production, sterile filling, quality testing, and validated supply chains can limit the number of reliable suppliers. These barriers can support pricing during shortages but do not create the same value as enforceable product patents.
Which companies compete in the imipenem-cilastatin market?
Competition includes originator-linked products, generic injectable manufacturers, contract manufacturers, and regional suppliers. The exact supplier group varies by country and by hospital tender.
The competitive set typically includes companies with sterile injectable capabilities such as:
- Merck, through the historical Primaxin franchise
- Sandoz
- Fresenius Kabi
- Hikma
- Pfizer and legacy Hospira operations
- Cipla
- Aurobindo
- Sun Pharmaceutical
- Viatris and other regional generic suppliers
Not every company markets the product in every jurisdiction. Approved strengths, supply status, and local tender participation differ by country.
The main therapeutic competitors are:
| Product |
Commercial position |
| Meropenem |
Major carbapenem competitor with broad hospital use |
| Ertapenem |
Once-daily option with narrower spectrum |
| Piperacillin-tazobactam |
Common broad-spectrum alternative |
| Cefepime-based regimens |
Used when carbapenem coverage is unnecessary |
| Ceftazidime-avibactam |
Protected or higher-value option for selected resistant infections |
| Ceftolozane-tazobactam |
Targeted resistant-gram-negative treatment |
| Recarbrio |
Higher-value imipenem-based product with relebactam |
Meropenem is the closest large-scale competitor in many hospital markets. It is often preferred because of dosing, institutional protocols, local susceptibility patterns, and formulary history.
What is the market size and financial trajectory of imipenem-cilastatin?
Public companies generally do not disclose standalone revenue for generic imipenem-cilastatin. Merck also does not report legacy Primaxin revenue as a separate current growth business. Market-research estimates for the global product category vary because they use different definitions of geography, dosage form, branded versus generic sales, and hospital procurement.
The financial trajectory is clear even without a single audited market total:
- The original brand generated high-value hospital antibiotic revenue during the patent-protected period.
- Generic entry caused substantial price erosion.
- Volume remained resilient because serious infections require inpatient broad-spectrum therapy.
- Revenue shifted from intellectual-property pricing to tender volume.
- Supply disruptions periodically improved pricing for capable manufacturers.
- Recarbrio created a separate, higher-value revenue stream with patent protection.
The generic product is therefore a low-margin, operationally sensitive business. Profitability depends on:
- Manufacturing scale
- API procurement
- Sterile-facility utilization
- Government and hospital contracts
- Product availability
- Recall history
- Cost of quality compliance
- Regional pricing rules
A supplier with reliable capacity can earn attractive returns during shortages, but those returns are vulnerable to new entrants and tender repricing.
What generic entry risks exist for imipenem-cilastatin?
Generic entry risk is already realized rather than prospective. The principal commercial risk is further price compression from additional suppliers, particularly in high-volume hospital markets.
Generic manufacturers face several practical risks:
- FDA inspection findings
- Sterility failures
- Batch rejection
- Short dating
- Imipenem degradation
- API supply interruption
- Hospital substitution rules
- Tender losses
- Antimicrobial stewardship restrictions
- Low utilization in markets shifting toward meropenem
The product also faces demand substitution. Hospitals may reduce use of imipenem-cilastatin where meropenem has better formulary positioning or where local resistance patterns favor another agent.
What manufacturing and intellectual-property barriers affect the market?
Manufacturing is more important than patent exclusivity. The product requires a validated sterile injectable process and controls for imipenem stability. The value chain includes:
- Qualified imipenem API
- Cilastatin API
- Sterile blending or aseptic processing
- Validated filling and lyophilization where applicable
- Container-closure integrity
- Stability testing
- Cold-chain or controlled-storage logistics
- Regulatory compliance across target markets
Process patents may restrict a particular production route, but a generic entrant can often design around expired or narrow claims. Trade secrets, manufacturing yield, impurity control, and scale-up expertise can be harder to replicate.
What licensing deals affect imipenem-cilastatin?
There is no major current licensing transaction that defines the standard generic imipenem-cilastatin market. Historical commercial rights were associated with Merck's development and commercialization of Primaxin. Current arrangements are more likely to involve:
- Contract manufacturing
- API supply
- Regional distribution
- Hospital purchasing agreements
- Authorized generic supply
- Licensing or commercialization of newer combinations
Recarbrio is commercially more important for licensing analysis because it combines imipenem-cilastatin with relebactam and has a separate development and regulatory history.
What patent litigation affects imipenem-cilastatin?
There is no major active litigation landscape comparable to that surrounding newer protected antibiotics. Legacy litigation would generally involve historical generic entry, manufacturing claims, or product-specific disputes rather than a current challenge to core imipenem-cilastatin exclusivity.
Litigation risk remains relevant for a company launching:
- A new formulation
- A premixed injectable
- A new dosage presentation
- A combination with a beta-lactamase inhibitor
- A process that may practice a surviving patent claim
The standard generic product has low litigation exposure but high regulatory and supply-chain exposure.
How does imipenem-cilastatin compare with Recarbrio?
Recarbrio has a stronger commercial and patent profile because relebactam expands activity against selected beta-lactamase-producing organisms. It also carries branded-product pricing and a more recent regulatory approval.
| Metric |
Imipenem-cilastatin |
Recarbrio |
| Product type |
Mature generic combination |
Newer branded combination |
| Added active ingredient |
None |
Relebactam |
| Patent status |
Core patents expired |
Separate active patent estate may apply |
| Revenue model |
Tender and volume |
Branded hospital pricing |
| Main value driver |
Availability and cost |
Resistance coverage and clinical positioning |
| Generic exposure |
High |
Lower before relevant patent expiry |
| Biosimilar exposure |
None |
None |
Recarbrio does not eliminate the generic market. It serves a narrower population and carries a different budget impact. Hospitals may reserve it for resistant infections while using generic imipenem-cilastatin for susceptible or empiric indications.
What is the outlook for imipenem-cilastatin revenue?
Revenue should remain stable to modestly declining in mature markets, with periodic increases tied to shortages, antimicrobial-resistance events, or hospital demand. Long-term growth is unlikely without a differentiated formulation, regional expansion, or combination product.
The most defensible commercial opportunities are:
- Low-cost, reliable sterile supply
- Markets with limited local manufacturing
- Government procurement
- Hospitals experiencing shortages
- Contract manufacturing for regional brands
- New combinations that address resistant pathogens
The weakest strategy is a premium-priced standard product without a supply, formulation, or geographic advantage.
Key Takeaways
- Imipenem-cilastatin is a mature, off-patent intravenous carbapenem.
- The original Primaxin franchise lost meaningful exclusivity decades ago.
- Standard products face generic competition and low intellectual-property barriers.
- No biosimilar pathway applies because the product is a small-molecule antibiotic.
- Current value is driven by hospital volume, tenders, manufacturing quality, and supply reliability.
- Meropenem is the principal competitive pressure in many hospital markets.
- Recarbrio is a separate, higher-value imipenem-based product with relebactam and a newer patent estate.
- Standard imipenem-cilastatin revenue is generally not disclosed separately by manufacturers.
- Shortages can temporarily improve pricing, but additional generic capacity can rapidly reverse those gains.
- Manufacturing know-how and sterile-injectable execution are more important than core patent protection.
FAQs
Is cilastatin sodium an antibiotic by itself?
No. Cilastatin inhibits renal dehydropeptidase-I and protects imipenem from degradation. Imipenem provides the antibacterial activity.
Is imipenem-cilastatin still protected by patents?
The core imipenem-cilastatin product is no longer protected by commercially meaningful composition patents in the United States. Product-specific formulation or manufacturing claims require separate analysis.
Can generic manufacturers launch imipenem-cilastatin without a Paragraph IV lawsuit?
Yes. Because core product protection has expired, a generic applicant may rely on standard abbreviated approval pathways. Paragraph IV issues mainly arise if a relevant listed patent remains associated with a particular product or presentation.
Does imipenem-cilastatin have biosimilar competition?
No. Imipenem-cilastatin is a chemically synthesized small-molecule drug, so competition proceeds through generic drug pathways rather than biosimilar applications.
Why can a generic imipenem-cilastatin product remain profitable after patent expiry?
Profitability can persist when a supplier has low manufacturing costs, reliable sterile capacity, strong hospital contracts, or access to markets with limited competition. Shortages can also temporarily support pricing.
References
-
U.S. Food and Drug Administration. (2019). PRIMAXIN IV: Imipenem and cilastatin sodium injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2019). RECARBRIO: Imipenem, cilastatin, and relebactam for injection prescribing information. FDA.
-
Merck & Co., Inc. (1985). Primaxin product and regulatory materials. Merck.
-
World Health Organization. (2023). 2023 antibacterial agents in clinical and preclinical development: An overview and analysis. WHO.
-
U.S. Food and Drug Administration. (2023). Drug shortages: Injectable antibacterial products and supply information. FDA.
